Entries by Thomas Gabrielczyk

European biotech stocks: New wave of optimism

In 2017, the European biotech sector witnessed a volume increase in IPOs and follow-on financings. This says the most recent capital market report of BIOCOM which is published during BIO-Europe on November 6.

NousCom raises €42m

Swiss oncolytic virus and vaccine specialist NousCom has closed a €42m Series B financing round led by new investor Abingworth. Co-investors include new 5AM Ventures, and existing investors LSP and Versant Ventures.

Another death related to allogenic CAR-T cell therapy

Following the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trials with UCART123, French Cellectis SA’s allogenic CAR-T therapies. Preliminary results from two trials in CD19+ relapsed or refractory B-Cell acute lymphoblastic leukemia patients dosed with UCART19 suggest that cytokine release syndrome (CRS) associated with allogenic CAR-T’s must be managed very carefully. 

Ablynx raises US$230m

Belgian nanobody producer Ablynx closes an initial public offering of American Depositary Shares at Nasdaq totalling US$200m plus a fully exercised greenshoe option amounting aggregate gross proceeds to US$230.

CPHI Worldwide expands outreach

The world’s largest event for pharma professionals, CPHI worldwide, will see an expansion to the rapidly-growing field of biologics next year in Madrid

Insight into biomarkers

AYOXXA’s LUNARIS platform:?In a case study "Translational proteomics: a new perspective for
ophthalmology research, Ayoxxa gives insights into the capabilities of its Lunaris multiplex protein
analysis platform.